The American Journal of Medicine
Volume 122, Issue 7 , Pages 647-655 , July 2009

Effect of Statin Adherence on Cerebrovascular Disease in Primary Prevention

  • Sylvie Perreault, BPharm, PhD

      Affiliations

    • Faculty of Pharmacy, University of Montreal, Quebec, Canada
    • Corresponding Author InformationRequests for reprints should be addressed to Sylvie Perreault, BPharm, PhD, Faculty of Pharmacy, University of Montreal, PO Box 6128, Centre-Ville Station, Montréal, Québec H3C 3J7, Canada
    • ,
  • Laura Ellia, MSc

      Affiliations

    • Faculty of Pharmacy, University of Montreal, Quebec, Canada
    • ,
  • Alice Dragomir, MSc

      Affiliations

    • Faculty of Pharmacy, University of Montreal, Quebec, Canada
    • ,
  • Robert Côté, MD, FRCPC

      Affiliations

    • Faculty of Medicine, McGill University, Montreal, Quebec, Canada
    • ,
  • Lucie Blais, PhD

      Affiliations

    • Faculty of Pharmacy, University of Montreal, Quebec, Canada
    • ,
  • Anick Bérard, PhD

      Affiliations

    • Faculty of Pharmacy, University of Montreal, Quebec, Canada
    • ,
  • Lyne Lalonde, BPharm, PhD

      Affiliations

    • Faculty of Pharmacy, University of Montreal, Quebec, Canada

References 

  1. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:1583–1633
  2. Heart and Stroke Foundation of Canada. The Growing Burden of Heart Disease and Stroke in Canada, 2003. Ottawa, Canada: Heart and Stroke Foundation of Canada; 2003;
  3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  5. Sever PS, Poulter NR, Dahlöf B, Wedel H. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
  6. Colhoum HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  7. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630
  8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (West of Scotland Coronary Prevention Study Group). N Engl J Med. 1995;333:1301–1308
  9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study). JAMA. 1998;279:1615–1622
  10. Larosa JC, Grundy AM, Waters DD, et al. Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  11. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2004;117:596–606
  12. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:2307–2313
  13. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med. 2008;121:24–33
  14. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statin. Lancet. 2005;366:1267–1278
  15. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757–767
  16. Amarenco P, Labreuche J, Lavallée Philippa , Touboul PJ. Statin in stroke prevention and carotic atherosclerosis (Systematic review and up-to-date meta-analysis). Lancet. 2004;356:2902–2909
  17. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455–461
  18. Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol. 2005;59:564–573
  19. International Classification of Diseases. Manual of the International Statistical Classification of Diseases, Injuries, and Cause of Death. 9th edn.. Geneva, Switzerland: World Health Organization; 1977;Publication no PHS 80-1260
  20. Minister of Supply and Services Canada. Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures. 2nd edn.. Ottawa, Ontario, Canada: Statistics Canada Health Division; 1986;
  21. Régie d'assurance maladie du Québec. Principales variables selon la catégorie de personnes assures [French]. Studies and Statistics 2005 http://www.ramq.gouv.qc.caAccessed September 20, 2006
  22. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48:999–1009
  23. Wilchesky M, Tamblyn R, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol. 2004;57:131–141
  24. Tirschwell DL, Longstreth WT. Validating administrative data in stroke research. Stroke. 2002;33:2465–2470
  25. Ernster VL. Nested case-control studies. Prev Med. 1994;23:587–590
  26. Essebag V, Genest J, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J. 2003;146:581–590
  27. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:449–457
  28. LaRosa JC, He J, Vupputuri S. Effect of statins risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–2346
  29. Kendrach M, Kelly-Freeman M. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacother. 2004;38:1286–1292
  30. Jones P, Kafonet S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. Am J Cardiol. 1998;81:582–587
  31. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197–203
  32. Essebag V, Platt R, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Method. 2005;5:5–11
  33. Greenland S. Sensitivity analysis, Monte Carlo risk analysis, and Bayesian uncertainty assessment. Risk Anal. 2001;21:579–583
  34. Steenland K, Greenland S. Monte Carlo sensitivity analysis and Bayesian analysis of smoking as an unmeasured confounder in a study of silica and lung cancer. Am J Epidemiol. 2004;160:384–392
  35. Greene WH. Econometric Analysis. 3rd edn.. Upper Saddle River, NJ: Prentice-Hall; 1997;
  36. Belsley DA, Kuy E, Welsch RE. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity. New York: John Wiley & Sons; 1981;
  37. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels (Cholesterol and Recurrent Events (CARE) Investigators). Circulation. 1998;98:839–844
  38. Ridker PM, Rifai N, Clearfield M, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–1965
  39. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926–933
  40. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med. 1995;332:512–521
  41. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643–1650
  42. Takemoto M, Liao JK. Pleiotrophic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712–1719
  43. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497
  44. Sacco RL, Benjamin EJ, Broderick JP, et al. Risk factors. Stroke. 1997;28:1507–1517
  45. Kim YS, Sunwoo S, Lee HR, et al. Korea Post-Marketing Surveillance Research Group Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf. 2002;11:593–600

 Funding: Financial support was received from the Canadian Institutes of Health Research.

 Conflict of Interest: None.

 Authorship: All coauthors have read and approved the manuscript, which represents, to the best of our knowledge, honest and accurate work.

PII: S0002-9343(09)00286-1

doi: 10.1016/j.amjmed.2009.01.032

The American Journal of Medicine
Volume 122, Issue 7 , Pages 647-655 , July 2009

Article Tools

* Image Usage & Resolution